Payer Insights: RA [2016]: Bulletin #2
This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara (sarilumab); recent approvals of biosimilar Enbrel and biosimilar Humira in the EU; and Eli Lilly/Incyte’s Olumiant (baricitinib) gaining marketing authorisation in the EU.
Business Questions
Business Questions
- How do payers intend to cover sarilumab? Will there be any restrictions?
- Is sarilumab likely to be utilised as a first or second-line therapy?
- What factors will determine the incorporation of sarilumab in formularies? What role will drug pricing and treatment guidelines play?
- Will biosimilars of Enbrel and Humira capture market share from branded anti-TNFs?
- Will the availability of biosimilar anti-TNFs improve patient access to RA treatment?
- What role will payers play in switching patients to biosimilar anti-TNFs?
- What patient subset will be targeted for switching to biosimilar anti-TNFs?
- On what factors will the uptake of biosimilars be dependent on?
- Will payers prefer biosimilars of Enbrel over biosimilars of Humira?
- How are biosimilars of Remicade viewed by payers?
- Are payers surprised that baricitinib was declined approval in the US, but not in the EU?
- How important will discounts on baricitinib be for making reimbursement decisions?
- Will the RA treatment paradigm shift towards oral and/or biosimilar agents?
